EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer

Shengnan Ren, Lingxin Feng, Haoran Liu, Yuke Mao, Zhuang Yu iD

Thoracic Cancer · 2024-05 · 15 (14) · 1149-1163

DOI: 10.1111/1759-7714.15303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 04.04.2024. Verfasst von Shengnan Ren und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Gastrointestinal Microbiome, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Natural Science Foundation of Qingdao Municipality, Wu Jieping Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy has revolutionized cancer treatment. Recent studies have suggested that the efficacy of immunotherapy can be further enhanced by the influence of gut microbiota. In this study, we aimed to investigate the impact of bacteria on the effectiveness of cancer immunotherapy by combining analysis of clinical samples with validation in animal models.

Methods

In order to characterize the diversity and composition of microbiota and its relationship with response to immune checkpoint inhibitors (ICIs), 16S ribosomal RNA (rRNA) and GC–MS sequencing was performed on 71 stool samples from patients with advanced non‐small cell lung cancer (NSCLC) prior to treatment with immune checkpoint blockade (ICB). Furthermore, fecal microbiota transplantation (FMT) was performed from different patients into mice and a subcutaneous tumor model established using the Lewis lung cancer cell line to evaluate the therapeutic effect of PD‐1 on mice with varying gut microbiota.

Results

The results demonstrated a significant association between elevated gut microbiota diversity and response to treatment with ICIs, p < 0.05. Faecalibacterium was markedly increased in the gut microbiota of responders (R), accompanied by increased short‐chain fatty acid (SCFA) levels, especially butanoic acid, acetic acid and hexanoic acid, p < 0.05. Additionally, FMT from R and nonresponders (NR) could promote an anticancer effect and reduce the expression of Ki‐67 cells in tumors in mice, p < 0.05. Moreover, R and NR FMT did not alter PD‐L1 expression in the tumor tissues of mice, p > 0.05. The diversity of gut microbiota consistently correlated with an optimistic prognosis in NSCLC patients with immunotherapy, which could be functionally mediated by SCFAs.

Conclusion

The findings of the present study indicated that the diversity of gut microbiota and SCFAs is related to the efficacy of immunotherapy. FMT can effectively delay tumor progression, and enhance the effect of immunotherapy, thus providing evidence for improving the efficacy of immunotherapy in NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungGastrointestinal MicrobiomeLung NeoplasmsImmunotherapyAnimalsMiceHumansFemaleMaleMiddle AgedAgedImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

biomarkerfecal microbiota transfer (FMT)gut microbiotaimmunotherapynon‐small cell lung cancer (NSCLC)

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao, China.

ORCID-Profile: Zhuang Yu

Förderung

  • Natural Science Foundation of Shandong Province
  • Natural Science Foundation of Qingdao Municipality
  • Wu Jieping Medical Foundation
  • National Natural Science Foundation of China
  • Chinese Society of Clinical Oncology
  • ShanDong Provincial Medical Association

Zitieren

APA

Ren, S., Feng, L., Liu, H., Mao, Y., & Yu, Z. (2024). Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer. Thoracic Cancer, 15(14), 1149-1163. https://doi.org/10.1111/1759-7714.15303

Vancouver

Ren S, Feng L, Liu H, Mao Y, Yu Z. Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer. Thoracic Cancer. 2024;15(14):1149-1163. doi:10.1111/1759-7714.15303

BibTeX
@article{Ren2024,
  author = {Ren, Shengnan and Feng, Lingxin and Liu, Haoran and Mao, Yuke and Yu, Zhuang},
  title = {Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer},
  journal = {Thoracic Cancer},
  year = {2024},
  volume = {15},
  number = {14},
  pages = {1149--1163},
  doi = {10.1111/1759-7714.15303}
}
Kostenlos starten →